Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs

A new report reveals the orphan drug market has grown at approximately double the overall growth of the prescription market. 

Highlights of the EvaluatePharma Orphan Drug Report 2017 include

• Worldwide orphan drug sales forecast to total $209bn (CAGR 2017 to 2022:+11.1%)

• Orphan drugs set to be 21.4% of worldwide prescription sales by 2022 (excluding generics)

• Median cost per patient 5.5 times higher for orphan drugs compared to non-orphan

• Celgene set to climb to number one position in orphan drug sales to 2022

• Shire to be largest company by sales in the orphan non-oncology space in 2022

• AstraZeneca, Abbvie and Johnson & Johnson set to march up the orphan drug sales ranking table

• Revlimid (lenalidomide) No.1 orphan drug in 2022

• Opdivo (nivolumab) No.1 orphan drug in Europe in 2022

• Orphan drugs forecast to account for 55% of the cumulative value of the European pipeline to 2022

• Axicabtagene Ciloleucel (Kite Pharma) is most valuable R&D orphan drug

•  First decline since 2012 for FDA orphan designations in 2016 with 333; Record number of applications made to the FDA for orphan designation in 2016

The “EvaluatePharma Orphan Drug Report 2017” can be downloaded at: www.evaluategroup.com/orphandrug2017.